Involvement of the NF-κB signaling pathway in the renoprotective effects of isorhamnetin in a type 2 diabetic rat model

Qiu,Shujuan; Sun,Guiling; Zhang,Yunxia; Li,Xiangling; Wang,Rong

doi:10.3892/br.2016.636

Involvement of the NF-κB signaling pathway in the renoprotective effects of isorhamnetin in a type 2 diabetic rat model

Authors:
- Shujuan Qiu
- Guiling Sun
- Yunxia Zhang
- Xiangling Li
- Rong Wang
View Affiliations

Affiliations: Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China, Blood Purification Center, Afﬁliated Hospital of Weifang Medical College, Weifang, Shandong 261053, P.R. China, Department of Nephrology, Afﬁliated Hospital of Weifang Medical College, Weifang, Shandong 261053, P.R. China
Published online on: March 22, 2016 https://doi.org/10.3892/br.2016.636
Pages: 628-634

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the renoprotective effects of isorhamnetin (ISO) in type 2 diabetic rats and its effects on the nuclear factor-κB (NF-κB) signaling pathway, which is associated with diabetic nephropathy. The type 2 diabetic rat model was established by a high‑fat diet plus streptozocin injection and the rats were subsequently treated with two dosages of ISO, respectively. The levels of blood glucose were determined. Urinary osteopontin, kidney injury molecule‑1 (KIM‑1) and albumin were measured to evaluate the renal function of the rats. Renal NF‑κB signaling activity was assessed by measuring the levels of NF‑κB p65, phospho‑NF‑κB p65, inhibitor of NF‑κB (IκBα) and phospho‑IκBα, and the NF‑κB p65 DNA‑binding activity. Downstream inflammatory mediators [tumor necrosis factor‑α (TNF‑α), interleukin‑1β (IL‑1β), IL‑6, intercellular adhesion molecule‑1 (ICAM‑1) and transforming growth factor‑β1 (TGF‑β1)] of the NF‑κB signaling pathway were investigated to evaluate the renal inflammatory response. Renal levels of malondialdehyde and total superoxide dismutase were detected to access the oxidative stress. Furthermore, glomerular mesangial cells (GMCs) were treated with lipopolysaccharide and ISO. In the cellular experiment, the NF‑κB signaling activity, levels of TNF‑α, IL‑1β, IL‑6, ICAM‑1 and TGF‑β1, and oxidative stress were also investigated. The results showed that ISO decreased the levels of urinary osteopontin, KIM‑1 and albumin. ISO also inhibited the NF‑κB signaling activity, decreased the production of inflammatory mediators and attenuated oxidative stress in diabetic rats and GMCs. The present investigations revealed that ISO had ameliorative effects on diabetes‑induced renal damage and the activity may be associated with the negative regulation of NF-κB signaling pathway.

View Figures

View References

1	Si X, Li P, Zhang Y, Zhang Y, Lv W and Qi D: Renoprotective effects of olmesartan medoxomil on diabetic nephropathy in streptozotocin-induced diabetes in rats. Biomed Rep. 2:24–28. 2014.PubMed/NCBI
2	Downs CA and Faulkner MS: Toxic stress, inflammation and symptomatology of chronic complications in diabetes. World J Diabetes. 6:554–565. 2015.PubMed/NCBI
3	Barutta F, Bruno G, Grimaldi S and Gruden G: Inflammation in diabetic nephropathy: Moving toward clinical biomarkers and targets for treatment. Endocrine. 48:730–742. 2015. View Article : Google Scholar : PubMed/NCBI
4	García-García PM, Getino-Melián MA, Domínguez-Pimentel V and Navarro-González JF: Inflammation in diabetic kidney disease. World J Diabetes. 5:431–443. 2014. View Article : Google Scholar : PubMed/NCBI
5	Yi B, Hu X, Zhang H, Huang J, Liu J, Hu J, Li W and Huang L: Nuclear NF-κB p65 in peripheral blood mononuclear cells correlates with urinary MCP-1, RANTES and the severity of type 2 diabetic nephropathy. PLoS One. 9:e996332014. View Article : Google Scholar : PubMed/NCBI
6	Ahad A, Ganai AA, Mujeeb M and Siddiqui WA: Ellagic acid, an NF-κB inhibitor, ameliorates renal function in experimental diabetic nephropathy. Chem Biol Interact. 219:64–75. 2014. View Article : Google Scholar : PubMed/NCBI
7	Yang SM, Ka SM, Wu HL, Yeh YC, Kuo CH, Hua KF, Shi GY, Hung YJ, Hsiao FC, Yang SS, et al: Thrombomodulin domain 1 ameliorates diabetic nephropathy in mice via anti-NF-κB/NLRP3 inflammasome-mediated inflammation, enhancement of NRF2 antioxidant activity and inhibition of apoptosis. Diabetologia. 57:424–434. 2014. View Article : Google Scholar : PubMed/NCBI
8	Ahad A, Ahsan H, Mujeeb M and Siddiqui WA: Gallic acid ameliorates renal functions by inhibiting the activation of p38 MAPK in experimentally induced type 2 diabetic rats and cultured rat proximal tubular epithelial cells. Chem Biol Interact. 240:292–303. 2015. View Article : Google Scholar : PubMed/NCBI
9	Wu JS, Shi R, Lu X, Ma YM and Cheng NN: Combination of active components of Xiexin decoction ameliorates renal fibrosis through the inhibition of NF-κB and TGF-β1/Smad pathways in db/db diabetic mice. PLoS One. 10:e01226612015. View Article : Google Scholar : PubMed/NCBI
10	Gui D, Huang J, Guo Y, Chen J, Chen Y, Xiao W, Liu X and Wang N: Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-κB-mediated inflammatory genes expression. Cytokine. 61:970–977. 2013. View Article : Google Scholar : PubMed/NCBI
11	Nishikawa T, Brownlee M and Araki E: Mitochondrial reactive oxygen species in the pathogenesis of early diabetic nephropathy. J Diabetes Investig. 6:137–139. 2015. View Article : Google Scholar : PubMed/NCBI
12	Kamiyama M, Urushihara M, Morikawa T, Konishi Y, Imanishi M, Nishiyama A and Kobori H: Oxidative stress/angiotensinogen/renin-angiotensin system axis in patients with diabetic nephropathy. Int J Mol Sci. 14:23045–23062. 2013. View Article : Google Scholar : PubMed/NCBI
13	Liu J, Wang C, Liu F, Lu Y and Cheng J: Metabonomics revealed xanthine oxidase-induced oxidative stress and inflammation in the pathogenesis of diabetic nephropathy. Anal Bioanal Chem. 407:2569–2579. 2015. View Article : Google Scholar : PubMed/NCBI
14	Tabur S, Korkmaz H, Eren MA, Oğuz E, Sabuncu T and Aksoy N: Urotensin-II level and its association with oxidative stress in early diabetic nephropathy. J Diabetes Complications. 29:115–119. 2015. View Article : Google Scholar : PubMed/NCBI
15	Mao ZM, Shen SM, Wan YG, Sun W, Chen HL, Huang MM, Yang JJ, Wu W, Tang HT and Tang RM: Huangkui capsule attenuates renal fibrosis in diabetic nephropathy rats through regulating oxidative stress and p38MAPK/Akt pathways, compared to α-lipoic acid. J Ethnopharmacol. 173:256–265. 2015. View Article : Google Scholar : PubMed/NCBI
16	Pal PB, Sinha K and Sil PC: Mangiferin attenuates diabetic nephropathy by inhibiting oxidative stress mediated signaling cascade, TNFα related and mitochondrial dependent apoptotic pathways in streptozotocin-induced diabetic rats. PLoS One. 9:e1072202014. View Article : Google Scholar : PubMed/NCBI
17	Kolati SR, Kasala ER, Bodduluru LN, Mahareddy JR, Uppulapu SK, Gogoi R, Barua CC and Lahkar M: BAY 11–7082 ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated oxidative stress and renal inflammation via NF-κB pathway. Environ Toxicol Pharmacol. 39:690–699. 2015. View Article : Google Scholar : PubMed/NCBI
18	Yang B, Li XP, Ni YF, Du HY, Wang R, Li MJ, Wang WC, Li MM, Wang XH, Li L, et al: Protective effect of isorhamnetin on lipopolysaccharide-induced acute lung injury in mice. Inflammation. 39:129–137. 2016. View Article : Google Scholar : PubMed/NCBI
19	Chen TL, Zhu GL, Wang JA, Zhang GD, Liu HF, Chen JR, Wang Y and He XL: Protective effects of isorhamnetin on apoptosis and inflammation in TNF-α-induced HUVECs injury. Int J Clin Exp Pathol. 8:2311–2320. 2015.PubMed/NCBI
20	Dou W, Zhang J, Li H, Kortagere S, Sun K, Ding L, Ren G, Wang Z and Mani S: Plant flavonol isorhamnetin attenuates chemically induced inflammatory bowel disease via a PXR-dependent pathway. J Nutr Biochem. 25:923–933. 2014. View Article : Google Scholar : PubMed/NCBI
21	Manu KA, Shanmugam MK, Ramachandran L, Li F, Siveen KS, Chinnathambi A, Zayed ME, Alharbi SA, Arfuso F, Kumar AP, et al: Isorhamnetin augments the anti-tumor effect of capeciatbine through the negative regulation of NF-κB signaling cascade in gastric cancer. Cancer Lett. 363:28–36. 2015. View Article : Google Scholar : PubMed/NCBI
22	Qian C, Zhu C, Yu W, Jiang X and Zhang F: High-fat diet/low-dose streptozotocin- induced type 2 diabetes in rats impacts ostegenesis and Wnt signaling in bone marrow stromal cells. PLoS One. 10:e01363902015. View Article : Google Scholar : PubMed/NCBI
23	Zimmet P, Alberti KG and Shaw J: Global and societal implications of the diabetes epidemic. Nature. 414:782–787. 2001. View Article : Google Scholar : PubMed/NCBI
24	Ruggenenti P, Cravedi P and Remuzzi G: The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol. 6:319–330. 2010. View Article : Google Scholar : PubMed/NCBI
25	Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z and Shahinfar S: RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 345:861–869. 2001. View Article : Google Scholar : PubMed/NCBI
26	Kim B, Choi YE and Kim HS: Eruca sativa and its flavonoid components, quercetin and isorhamnetin, improve skin barrier function by activation of peroxisome proliferator-activated receptor (PPAR)-α and suppression of inflammatory cytokines. Phytother Res. 28:1359–1366. 2014. View Article : Google Scholar : PubMed/NCBI
27	Yang JH, Shin BY, Han JY, Kim MG, Wi JE, Kim YW, Cho IJ, Kim SC, Shin SM and Ki SH: Isorhamnetin protects against oxidative stress by activating Nrf2 and inducing the expression of its target genes. Toxicol Appl Pharmacol. 274:293–301. 2014. View Article : Google Scholar : PubMed/NCBI
28	Dong GZ, Lee JH, Ki SH, Yang JH, Cho IJ, Kang SH, Zhao RJ, Kim SC and Kim YW: AMPK activation by isorhamnetin protects hepatocytes against oxidative stress and mitochondrial dysfunction. Eur J Pharmacol. 740:634–640. 2014. View Article : Google Scholar : PubMed/NCBI
29	Duran-Salgado MB and Rubio-Guerra AF: Diabetic nephropathy and inflammation. World J Diabetes. 5:393–398. 2014. View Article : Google Scholar : PubMed/NCBI
30	Lazaro I, Oguiza A, Recio C, Mallavia B, Madrigal-Matute J, Blanco J, Egido J, Martin-Ventura JL and Gomez-Guerrero C: Targeting HSP90 ameliorates nephropathy and atherosclerosis through suppression of NF-κB and STAT signaling pathways in diabetic mice. Diabetes. 64:3600–3613. 2015. View Article : Google Scholar : PubMed/NCBI
31	Sakai N and Wada T: Revisiting inflammation in diabetic nephropathy: The role of the Nlrp3 inflammasome in glomerular resident cells. Kidney Int. 87:12–14. 2015. View Article : Google Scholar : PubMed/NCBI
32	Jin JY, Choi EY, Park HR, Choi JI, Choi IS and Kim SJ: Isorhamnetin inhibits Prevotella intermedia lipopolysaccharide-induced production of interleukin-6 in murine macrophages via anti-inflammatory heme oxygenase-1 induction and inhibition of nuclear factor-κB and signal transducer and activator of transcription 1 activation. J Periodontal Res. 48:687–695. 2013.PubMed/NCBI
33	Muchová J, Országhová Z, Žitnanová I, Trebatický B, Breza J and Duracková Z: The effect of natural polyphenols on the oxidative stress markers in patients with diabetic nephropathy. Free Radic Biol Med. 75(Suppl 1): S422014. View Article : Google Scholar
34	Verma AK, Chandra S, Singh RG, Singh TB, Srivastava S and Srivastava R: Serum prolidase activity and oxidative stress in diabetic nephropathy and end stage renal disease: a correlative study with glucose and creatinine. Biochem Res Int. 2014:2914582014. View Article : Google Scholar : PubMed/NCBI
35	Gomes IB, Porto ML, Santos MC, Campagnaro BP, Pereira TM, Meyrelles SS and Vasquez EC: Renoprotective, anti-oxidative and anti-apoptotic effects of oral low-dose quercetin in the C57BL/6J model of diabetic nephropathy. Lipids Health Dis. 13:1842014. View Article : Google Scholar : PubMed/NCBI
36	Mima A: Inflammation and oxidative stress in diabetic nephropathy: new insights on its inhibition as new therapeutic targets. J Diabetes Res. 2013:2485632013. View Article : Google Scholar : PubMed/NCBI
37	Bao M and Lou Y: Isorhamnetin prevent endothelial cell injuries from oxidized LDL via activation of p38MAPK. Eur J Pharmacol. 547:22–30. 2006. View Article : Google Scholar : PubMed/NCBI
38	Han X, Piao MJ, Kim KC, Madduma Hewage SR, Yoo ES, Koh YS, Kang HK, Shin JH, Park Y, Yoo SJ, et al: Isorhamnetin Protects Human Keratinocytes against Ultraviolet B-Induced Cell Damage. Biomol Ther (Seoul). 23:357–366. 2015. View Article : Google Scholar : PubMed/NCBI
39	Ding Y, Yang H, Xiang W, He X, Liao W and Yi Z: CD200R1 agonist attenuates LPS-induced inflammatory response in human renal proximal tubular epithelial cells by regulating TLR4-MyD88-TAK1-mediated NF-κB and MAPK pathway. Biochem Biophys Res Commun. 460:287–294. 2015. View Article : Google Scholar : PubMed/NCBI